Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 6,165 Shares of Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Daljit Singh Aurora sold 6,165 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $3.56, for a total value of $21,947.40. Following the completion of the sale, the insider owned 82,770 shares of the company’s stock, valued at approximately $294,661.20. This trade represents a 6.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Neumora Therapeutics Stock Down 3.1%

Shares of NMRA stock traded down $0.11 during trading hours on Thursday, reaching $3.48. 1,491,798 shares of the company’s stock were exchanged, compared to its average volume of 2,331,130. Neumora Therapeutics, Inc. has a 1 year low of $0.61 and a 1 year high of $3.65. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. The stock has a market cap of $581.47 million, a PE ratio of -2.37 and a beta of 3.20. The stock’s fifty day moving average price is $2.15 and its two-hundred day moving average price is $2.05.

Analysts Set New Price Targets

NMRA has been the subject of a number of research analyst reports. Leerink Partners initiated coverage on shares of Neumora Therapeutics in a report on Monday, January 12th. They issued an “outperform” rating and a $8.00 price target for the company. William Blair raised Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday. Guggenheim upgraded Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Monday, October 27th. Stifel Nicolaus boosted their price target on Neumora Therapeutics from $2.00 to $3.00 and gave the company a “hold” rating in a research note on Monday, November 17th. Finally, Mizuho set a $6.00 price objective on Neumora Therapeutics in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $8.13.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NMRA. AlphaCore Capital LLC purchased a new position in shares of Neumora Therapeutics in the second quarter valued at approximately $248,000. Catalyst Funds Management Pty Ltd acquired a new position in Neumora Therapeutics in the 2nd quarter valued at $29,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Neumora Therapeutics in the 2nd quarter valued at $41,000. Savant Capital LLC acquired a new stake in Neumora Therapeutics during the 2nd quarter worth $52,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Neumora Therapeutics during the second quarter worth $42,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.